Jacob L Hyllested-Winge

Suggest Changes
Learn More
BACKGROUND In separate randomized, crossover trials, patients with diabetes reported a preference for durable insulin pen NovoPen(®) 4 compared with NovoPen 3 and OptiClik(®). OBJECTIVE This large(More)
BACKGROUND The present study was a subgroup analysis of a Pan-Asian Phase 3 open-label randomized treat-to-target trial evaluating insulin degludec/insulin aspart (IDegAsp) and biphasic insulin(More)
  • 1